Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2010

View Archived Issues

NeuroSearch claims new nicotinic acetylcholine receptor modulators

Monthly and twice-monthly certolizumab pegol equally maintain responses in Crohn's disease patients

Studies reveal activity of DZNep in multiple myeloma and acute myeloid leukemia

RAV-12 antibody to be re-engineered for further clinical testing in cancer

Abbott claims new Rho kinase inhibitors

Novartis discloses novel CRF1 receptor antagonists

Menarini and Ipsen launch febuxostat in France for chronic hyperuricemia in gout

FDA's grant of 5-year market exclusivity to Vyvanse upheld in court

FDA approves CSL Behring's Hizentra immunoglobulin therapy

Avineuro reports phase I results on AVN-322 in Alzheimer's disease

Kapidex renamed Dexilant in U.S.

Doxazosin correlates with improved voiding dysfunction in Parkinson's disease

Bupivacaine alleviates bladder syndrome/interstitial cystitis pain in lidocaine-refractory patients

French scientists disclose new broad-spectrum ricin inhibitors

Isis initiates phase I trial of ISIS-SOD1Rx in patients with ALS

FDA accepts for review Biodel's VIAject NDA for diabetes

Anthera completes initial public offering and prepares A-002 trial

BioSante to raise funds in registered direct offering

ImmuneRegen applies for FDA orphan drug status for Homspera in IPF

Amarillo Biosciences and Intas sign license agreement for oral interferon to treat influenza

Adamis and La Jolla Pharmaceutical terminate merger agreement

Novartis claims novel antiviral agents

Chelsea Therapeutics completes registered direct offering to institutional investors

NicOx's naproxcinod NDA for osteoarthritis to be discussed by FDA advisory committees in May

Avid to present update on phase III clinical trials of AV-45

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...